Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Salix Pharmaceuticals, Ltd./Santarus, Inc. tender offer
| November 07, 2013 • Antitrust Risk-shifting • $2.6 billion |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.